About Us
Our Team
Our α-Klotho Story
Products
klotho neurosciences
Our Vision & Our Mission
Our vision is to build a leading gene therapy company for the treatment of neurodegenerative diseases by progressing our patented á-Klotho gene therapy research programs and identifying, developing, and commercializing other novel gene therapy treatments and in vitro diagnostics for neurodegenerative diseases, and other age-related pathologies.
We have assembled a portfolio of gene therapy candidates in partnership with leading scientific institutions and have built a team with extensive experience in the biotechnology commercialization and gene therapy space. Our team will pursue new innovations in vector design and delivery to optimize our investigational gene therapy products for safety, potency, durability, and clinical response. We plan on building integrated internal development capabilities from product development through commercialization and focus on accelerating the pace of product development in the clinic. In addition, as part of our ongoing business strategy, we continue to explore potential opportunities to acquire or license new product candidates as well as opportunities for partnership or collaboration on our existing products in development.
cell & gene therapies
Platform Technologies
- A cell therapy and gene therapy platform that uses a gene therapy approach to introduce a human gene into the body. That gene is our patent-protected secreted form of Klotho, s-KL. The s-KL gene when introduced into the body produces Klotho, a therapeutic protein to treat neurodegenerative diseases and other age-related disorders.
We have a highly experienced team managing our key cell therapy and gene therapy platform. In pursuing our mission of developing therapeutic agents based on the human á-Klotho gene, we will initially focus on the development of a treatment for amyotrophic lateral sclerosis (“ALS” or “Lou Gehrig’s Disease), followed by treatments for Alzheimer’s and Parkinson’s disease.
We believe that there is currently limited competition in our pursuit of the therapeutic potential of the human á-Klotho gene due to our strong intellectual property position and technology know-how. Thus, our portfolio of gene therapy candidates targets a broad spectrum of indications across many age-related diseases, and potentially “aging” itself.
In summary, Klotho Neurosciences was founded to develop and provide disruptive new therapies to alleviate and/or reverse the progression of neurodegenerative diseases through the use of cell and gene therapy. Our goal is to develop innovative treatments for people with amyotrophic lateral sclerosis (“ALS” or “Lou Gehrig’s Disease”), Alzheimer’s and Parkinson’s disease.
Our Pipeline
Developing Life-Extending
Cell and Gene Therapies